---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-012181"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T14:44:42.976937+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics enters $1.1M convertible note to fund pending SCN acquisition

## Summary
- $1.1M principal convertible note to V-Co Investors 2 LLC; net funding $1M after $100k fee.
- Zero interest unless default; default rate 15% p.a.; secured by equipment only on default.
- Converts automatically into equity of subsequent financing expected at SCN closing (target July 31, 2025).
- Proceeds to fund previously announced acquisition of The Sleep Center of Nevada.
- V-Co is affiliate of existing investor New Seneca Partners Inc.

## SEC filing metadata
- accession: 0001641172-25-012181
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000164117225012181/0001641172-25-012181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000164117225012181/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-012181
- JSON: https://secwatch.observer/filing/0001641172-25-012181.json
- Plain text: https://secwatch.observer/filing/0001641172-25-012181.txt

## Key facts
- Debt Financings
  Vivos Therapeutics, Inc. incurred convertible notes of $1,100,000 with V-Co Investors 2 LLC at 0% (15% per annum upon Event of Default) maturing No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date.
  - Instrument: convertible notes
  - Principal: $1,100,000
  - Counterparty: V-Co Investors 2 LLC
  - Rate: 0% (15% per annum upon Event of Default)
  - Maturity: No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date
  - Event: incurrence
  source text: On May 21, 2025, Vivos Therapeutics, Inc. (the “ Company ”) entered into a convertible promissory note in favor of V-Co Investors 2 LLC (“ V-Co ”) in the principal amount of $1,100,000 (the “ Note ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000164117225012181/0001641172-25-012181-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.